Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
FAIL · Does not pass the screen
3.46 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 10:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price3.46 USD at the 23 Oct 2026 close
Ethical screenDoes not pass
Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 3.46 against the desk's fair-value range, base estimate 6.69, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price3.46 USD
Fair value6.69
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Markdown4.41-21.5% to today ✓Accumulation gives way to Markdown first Markdown read since September
2026-10-02Read Accumulation4.41-21.5% to today Markdown gives way to Accumulation after a 14% rise in 4 weeks
2026-09-02Read Markdown3.86-10.4% to today ✓Accumulation gives way to Markdown first Markdown read since July
2026-08-02Read Accumulation3.86-10.4% to today Markdown gives way to Accumulation after a 6% rise in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Ironwood Pharmaceuticals Inc holds its Markdown at $3.46. The statistical read favours the sellers, held for 40 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 40 days
Price at the screen
$3.46
Valuation
7.11 trailing · 3.06 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.21
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
150.62%
Below 33%
Interest-bearing debt is 150.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
66.06%
Below 49%
Money owed to the company is 66.1% of assets, above the 49% limit.
Fail
Revenue purity
1.38%
Below 5%
Only 1.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Ironwood Pharmaceuticals's business is in a permissible area, but its interest-bearing debt is about 151% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when IRWD's ethical verdict changes
Today IRWD does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 93.3% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus Buy. The average target sits +55% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IRWD trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markdown$3.46-3.6%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 320%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it none, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$3.59-18.6%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 18.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 320%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it none, with a mean price target of $6.
2026-10-11Markdown · changed$4.41+0.0%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 320%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it none, with a mean price target of $6.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 14.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 320%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it none, with a mean price target of $6.
2026-09-02Markdown · changed$3.86+0.0%Entry 5
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 320%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it none, with a mean price target of $6.
2026-08-02Accumulation · changed$3.86+5.8%Entry 4
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 320%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it none, with a mean price target of $6.
2026-07-18Markdown$3.65+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 320%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it none, with a mean price target of $6.
2026-07-03Markdown$3.65+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$3.65Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.